Mark Nelson, PhD

Chief Executive Officer

Dr. Nelson is a cofounder of Precision Epigenomics, Inc. He is a professor and former co-interim chair of pathology at the University of Arizona. Dr. Nelson was the Senner Endowment for Precision Health chair and a Hogarty Family Foundation award winner has over 30 years of experience in cancer biology, genomics, molecular biology, and translational science. He has proven success in cross-functional leadership, operations, and strategic planning and has a strong business acumen.

Matthew Miller

Chief Financial Officer

Mr. Miller has over 35 years of healthcare experience. For the last 15+ years, he has worked as the chief financial officer for the largest diagnostic and interventional radiology services provider in southern Arizona.

Richard Bernert, MD, FCAP

Chief Operating Officer

Dr. Bernert is board certified in dermatopathology, anatomic pathology, and clinical pathology. He also has extensive public and private diagnostic laboratory management experience over his 25 years of practice. In addition, he has an extensive academic and professional society service background, complemented by distinguished military service.

Nannon Roosa, FACMPE, PMP, CPA

Vice President, Technology Licensing Strategy

Nannon Roosa, FACMPE, PMP, CPA, Vice President, Technology Licensing Strategy, is a seasoned entrepreneur and bioscience commercialization expert. As a Managing Partner with Crescent Edge Consulting and Commercialization Partner Tech Launch Arizona, she has played a pivotal role in launching bioscience technologies and guiding critical FDA clearances, as evidenced during her tenure with CATS Tonometer.

Joshua Routh, MD

Medical Director

Dr. Routh is board certified in molecular pathology, anatomic pathology, and clinical pathology. Dr. Routh has diagnostics and commercial product development experience. He also has expertise in machine learning approaches. In addition, Dr. Routh has considerable experience as a medical director of commercial diagnostic laboratories.

Lisa Shaffer, PhD

Board Member and Executive Chair

Dr. Shaffer is the founder and former CEO of Genetic Veterinary Sciences, Inc.® (DBA Paw Print Genetics). Prior to Paw Print Genetics®, she was the cofounder, president, and CEO of Signature Genomic Laboratories, Inc. Dr. Shaffer was named one of the top 10 women CEOs for privately held companies by INC Magazine and was named Businesswoman of the Year by Inland Business Catalyst Magazine. Dr. Shaffer received the Women in Business Leadership Award for the Spokane region in 2017. Dr. Shaffer serves as the executive chair of the board of directors for Precision Epigenomics.

Alisa Tubbs, MBA

Strategy & Commercialization Advisor

Alisa Tubbs, M.B.A. Strategy & Commercialization Advisor, is a seasoned diagnostics executive with end-to-end experience spanning early product development to global commercialization. Her expertise includes ideation, IP strategy and execution, regulatory and requirements planning, reimbursement strategy, market readiness, product launch, and international go-to-market execution.

Marie Wesselhoft

Board Member

Ms. Wesselhoft is president and cofounder of ZelosDx. She has upward of 35 years of healthcare business experience in the diagnostic, device, and provider industry. She has held positions such as vice president and general manager, vice president of marketing, area vice president of sales and operations, and product manager during her 20-year career at Cardinal/Baxter/American Hospital.

Jannalee Johnson

Director of Sales and Business Development

Mrs. Johnson brings extensive expertise in driving revenue growth, executing strategic planning, and fostering key client relationships across global diagnostic industries. With a proven track record in sales leadership and market expansion, she excels in delivering innovative solutions for diverse markets, including launching a women’s health laboratory, digital pathology, molecular diagnostics, and AI technologies. Mrs. Johnson’s passion for building high-performing teams and securing strategic partnerships underscores her commitment to achieving excellence and creating impactful results for the organization while making an impact in cancer diagnostics.

Who We Are

When you need answers, Precision Epigenomics delivers with earlier multi-cancer detection.

Precision Epigenomics is committed to transforming healthcare with cutting-edge technology that identifies multiple cancer types at their earliest stages through a simple liquid biopsy.

Driven by excellence and compassion, EPISEEK^® tests are fast, reliable, and affordable, giving patients the peace of mind they need about their health and future. We are more than just a business: We are a medically led team devoted to enhancing your well-being.